Testosteron (Turkish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Testosteron" in Turkish language version.

refsWebsite

Global rank Turkish rank

7nih.gov

4^th place

11^th place

6doi.org

2^nd place

4^th place

4archive.org

6^th place

2web.archive.org

1^st place

1mayoclinic.org

1,610^th place

1,902^nd place

1books.google.com

3^rd place

5^th place

1wada-ama.org

9,542^nd place

low place

archive.org

Southren AL, Gordon GG, Tochimoto S, Pinzon G, Lane DR, Stypulkowski W (May 1967). "Mean plasma concentration, metabolic clearance and basal plasma production rates of testosterone in normal young men and women using a constant infusion procedure: effect of time of day and plasma concentration on the metabolic clearance rate of testosterone". The Journal of Clinical Endocrinology & Metabolism. 27 (5): 686-94. doi:10.1210/jcem-27-5-686. PMID 6025472.
Southren AL, Tochimoto S, Carmody NC, Isurugi K (Nov 1965). "Plasma production rates of testosterone in normal adult men and women and in patients with the syndrome of feminizing testes". The Journal of Clinical Endocrinology & Metabolism. 25 (11): 1441-50. doi:10.1210/jcem-25-11-1441. PMID 5843701.
Dabbs M, Dabbs JM (2000). Heroes, rogues, and lovers: testosterone and behavior. New York: McGraw-Hill. ISBN 978-0-07-135739-5.
Dabbs M, Dabbs JM (2000). Heroes, rogues, and lovers: testosterone and behavior. New York: McGraw-Hill. ISBN 978-0-07-135739-5.

books.google.com

Luetjens, C. Marc; Weinbauer, Gerhard F. (2012). "Chapter 2: Testosterone: Biosynthesis, transport, metabolism and (non-genomic) actions". Nieschlag, Eberhard; Behre, Hermann M.; Nieschlag, Susan (Ed.). Testosterone: Action, Deficiency, Substitution (4. bas.). Cambridge: Cambridge University Press. ss. 15-32. ISBN 978-1-107-01290-5.

doi.org

Mooradian AD, Morley JE, Korenman SG (Feb 1987). "Biological actions of androgens". Endocrine Reviews. 8 (1): 1-28. doi:10.1210/edrv-8-1-1. PMID 3549275.
Bassil N, Alkaade S, Morley JE (Jun 2009). "The benefits and risks of testosterone replacement therapy: a review". Therapeutics and Clinical Risk Management. 5 (3): 427-48. doi:10.2147/tcrm.s3025. PMC 2701485 $2. PMID 19707253.
Tuck SP, Francis RM (2009). "Testosterone, bone and osteoporosis". Advances in the Management of Testosterone Deficiency. Frontiers of Hormone Research. 37. ss. 123-32. doi:10.1159/000176049. ISBN 978-3-8055-8622-1. PMID 19011293.
Torjesen PA, Sandnes L (Mar 2004). "Serum testosterone in women as measured by an automated immunoassay and a RIA". Clinical Chemistry. 50 (3): 678; author reply 678-9. doi:10.1373/clinchem.2003.027565 . PMID 14981046.
Southren AL, Gordon GG, Tochimoto S, Pinzon G, Lane DR, Stypulkowski W (May 1967). "Mean plasma concentration, metabolic clearance and basal plasma production rates of testosterone in normal young men and women using a constant infusion procedure: effect of time of day and plasma concentration on the metabolic clearance rate of testosterone". The Journal of Clinical Endocrinology & Metabolism. 27 (5): 686-94. doi:10.1210/jcem-27-5-686. PMID 6025472.
Southren AL, Tochimoto S, Carmody NC, Isurugi K (Nov 1965). "Plasma production rates of testosterone in normal adult men and women and in patients with the syndrome of feminizing testes". The Journal of Clinical Endocrinology & Metabolism. 25 (11): 1441-50. doi:10.1210/jcem-25-11-1441. PMID 5843701.

mayoclinic.org

"Understanding the risks of performance-enhancing drugs". Mayo Clinic (İngilizce). 21 Nisan 2020 tarihinde kaynağından arşivlendi. Erişim tarihi: 30 Aralık 2019.

nih.gov

ncbi.nlm.nih.gov

Mooradian AD, Morley JE, Korenman SG (Feb 1987). "Biological actions of androgens". Endocrine Reviews. 8 (1): 1-28. doi:10.1210/edrv-8-1-1. PMID 3549275.
Bassil N, Alkaade S, Morley JE (Jun 2009). "The benefits and risks of testosterone replacement therapy: a review". Therapeutics and Clinical Risk Management. 5 (3): 427-48. doi:10.2147/tcrm.s3025. PMC 2701485 $2. PMID 19707253.
Tuck SP, Francis RM (2009). "Testosterone, bone and osteoporosis". Advances in the Management of Testosterone Deficiency. Frontiers of Hormone Research. 37. ss. 123-32. doi:10.1159/000176049. ISBN 978-3-8055-8622-1. PMID 19011293.
Torjesen PA, Sandnes L (Mar 2004). "Serum testosterone in women as measured by an automated immunoassay and a RIA". Clinical Chemistry. 50 (3): 678; author reply 678-9. doi:10.1373/clinchem.2003.027565 . PMID 14981046.
Southren AL, Gordon GG, Tochimoto S, Pinzon G, Lane DR, Stypulkowski W (May 1967). "Mean plasma concentration, metabolic clearance and basal plasma production rates of testosterone in normal young men and women using a constant infusion procedure: effect of time of day and plasma concentration on the metabolic clearance rate of testosterone". The Journal of Clinical Endocrinology & Metabolism. 27 (5): 686-94. doi:10.1210/jcem-27-5-686. PMID 6025472.
Southren AL, Tochimoto S, Carmody NC, Isurugi K (Nov 1965). "Plasma production rates of testosterone in normal adult men and women and in patients with the syndrome of feminizing testes". The Journal of Clinical Endocrinology & Metabolism. 25 (11): 1441-50. doi:10.1210/jcem-25-11-1441. PMID 5843701.
Institute of Medicine (US) Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy; Liverman, Catharyn T.; Blazer, Dan G. (2004). "Introduction". Testosterone and Aging: Clinical Research Directions (İngilizce). National Academies Press (US).

wada-ama.org

"What is Prohibited". World Anti-Doping Agency (İngilizce). 12 Kasım 2020 tarihinde kaynağından arşivlendi. Erişim tarihi: 18 Temmuz 2021.

web.archive.org

"Understanding the risks of performance-enhancing drugs". Mayo Clinic (İngilizce). 21 Nisan 2020 tarihinde kaynağından arşivlendi. Erişim tarihi: 30 Aralık 2019.
"What is Prohibited". World Anti-Doping Agency (İngilizce). 12 Kasım 2020 tarihinde kaynağından arşivlendi. Erişim tarihi: 18 Temmuz 2021.